Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

Implementation of Evidence-Based Strategies to Optimize HPV Vaccination in Rural Primary Care Settings

Principal Investigator: Rodriguez, Elisa M

(ACNS1723) A Phase 2 Study of Dabrafenib (NCS#763760) with Trametinib (NCS# 763093) after Local Irradiation in Newly-Diagnosed BRAFv600-Mutant High-Grade Glioma (HGG) (IND#145355)

Principal Investigator: Twist, Clare J

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation

Principal Investigator: Fountzilas, Christos

(AALL1621) A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Principal Investigator: Twist, Clare J

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Principal Investigator: McCarthy, Philip L

A FIRST-IN-HUMAN, PHASE 1, DOSE ESCALATION STUDY OF SGR-2921 AS MONOTHERAPY IN SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME

Principal Investigator: Wang, Eunice S

(AALL1732) A Phase 3 Randomized Trial of Inotuzumab Ozogamicin(IND#:133494, NSC#:772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-InductionTherapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Principal Investigator: Twist, Clare J

Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Principal Investigator: Chatta, Gurkamal S

A Phase 1b/2, Open-Label, Safety, Tolerability And Efficacy Study Of NC410 Plus Pembrolizumab For Participants With Advanced Unresectable And/Or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors Or ICI Naïve MSS/MSI-Low Solid Tumors

Principal Investigator: Zsiros, Emese

A Randomized Phase 3 Trial of Continuous vs Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)

Principal Investigator: Pan, Dorothy

(ACNS1931) A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Principal Investigator: Barth, Matthew J

A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors

Principal Investigator: Mukherjee, Sarbajit

Asciminib as Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia who do not Achieve a Deep Molecular Remission (ALERT CML)

Principal Investigator: Thompson, J

Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma (Protocol GNS561-222-1)

Principal Investigator: Iyer, Renuka V

A first-in-human (FIH), phase 1, multicenter, open- label, dose escalation and expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally administered GLB-001 in patients with relapsed or refractory…

Principal Investigator: Wang, Eunice S

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

Principal Investigator: Bouchard, Elizabeth G

A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor…

Principal Investigator: Fountzilas, Christos

A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS NCI-supplied agent(s): Palbociclib (NSC #772256); Binimetinib (NSC #788187)

Principal Investigator: Levine, Ellis G

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and
a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Principal Investigator: Thanikachalam, Kannan

A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2 Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or…

Principal Investigator: Fountzilas, Christos

Phase 2 Trial of Belantamab Mafoditin Consolidation Treatment in Patients with Multiple Myeloma and MRD Positivity after Autologous Stem Cell Transplantation

Principal Investigator: Hillengass, Jens

An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

Medical Access Program for Patritumab Deruxtecan (HER3-DXd, U3-1402)

Principal Investigator: Dy, Grace K

Randomized Phase 2 Clinical Trial of Pembrolizumab Combined with Bevacizumab with or without Agonist Anti-CD40 CDX-1140 in Patients with Recurrent Ovarian Cancer

Principal Investigator: Zsiros, Emese